FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.
What happened
In December 2025, FDA reviewed BluefitMD's website and found it offered compounded (pharmacy-made) semaglutide and tirzepatide drug products. FDA said the pictured labels named BluefitMD, suggesting BluefitMD was the compounder when it was not. FDA also said website claims comparing the products to Ozempic, Wegovy, Mounjaro, and Zepbound implied FDA approval or evaluation that the compounded drugs do not have.
What FDA found
The website's labels name BluefitMD as the compounder of semaglutide and tirzepatide products when BluefitMD does not compound them, so the labeling is false or misleading.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; see 21 CFR § 201.1(h)(2)The website says compounded semaglutide has the same active ingredient as Ozempic and Wegovy, implying FDA approval or evaluation that the compounded product does not have.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says compounded tirzepatide has the same active ingredient as Mounjaro and Zepbound, implying FDA approval or evaluation that the compounded product does not have.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receipt or delivery of misbranded drugs in interstate commerce is also prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, BluefitMD must send CDER's Office of Compounding Quality and Compliance a written response describing steps taken to address the violations, identify the entities that produce the compounded products, provide sample labeling, and address or remove the misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- marketers of compounded drugs that compare products to brand-name drugs
- compounding pharmacies or manufacturers whose labels appear on telehealth sites
This is a summary. Read the original letter on fda.gov.